Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Primidone
Drug ID BADD_D01840
Description Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures.[L11112] Primidone was developed by J Yule Bogue and H C Carrington in 1949.[A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112]
Indications and Usage Primidone is commonly indicated for the management of grand mal, psychomotor, and focal epileptic seizures.[L4645,L11112] In addition, it has also been studied and utilized as an effective management of essential tremor.[A39414,A39415,L4645]
Marketing Status approved; vet_approved
ATC Code N03AA03
DrugBank ID DB00794
KEGG ID D00474
MeSH ID D011324
PubChem ID 4909
TTD Drug ID D0U5RT
NDC Product Code 72888-045; 72888-046; 53746-544; 71610-590; 59348-0001; 42291-511; 50090-4083; 71610-191; 55111-876; 52817-117; 63629-7811; 71610-079; 62135-468; 0591-5321; 71335-1965; 72888-160; 17205-308; 49452-6020; 81066-0002; 42291-509; 68084-202; 68084-203; 71335-1158; 65162-544; 66490-691; 0527-1301; 0615-8206; 69575-4045; 66490-690; 72789-177; 53746-545; 72189-216; 72789-178; 17205-307; 50268-686; 51407-637; 51407-638; 65162-545; 69584-685; 0527-1231; 71610-005; 71610-540; 55111-477; 69584-684; 50268-687; 55111-476
UNII 13AFD7670Q
Synonyms Primidone | Liskantin | Mylepsinum | Resimatil | Desoxyphenobarbital | Mizodin | Mysoline | Apo-Primidone | Apo Primidone | Primaclone | Sertan | Misodine | Primidon Holsten
Chemical Information
Molecular Formula C12H14N2O2
CAS Registry Number 125-33-7
SMILES CCC1(C(=O)NCNC1=O)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Granulocytopenia01.02.03.003---
Hallucination19.10.04.003--
Headache17.14.01.0010.001164%
Insomnia17.15.03.002; 19.02.01.002--
Irritability08.01.03.011; 19.04.02.0130.000342%
Malaise08.01.01.0030.001164%
Nausea07.01.07.0010.001336%
Nervous system disorder17.02.10.001---
Nervousness19.06.02.003---
Nystagmus06.05.02.006; 17.02.02.006--
Personality change17.02.05.019; 19.05.01.006--
Peyronie's disease21.12.01.0020.000685%-
Pruritus23.03.12.001--
Rash23.03.13.0010.001164%-
Rash morbilliform23.03.13.005---
Seizure17.12.03.0010.000342%
Skin disorder23.03.03.007---
Somnolence17.02.04.006; 19.02.05.0030.001336%
Suicidal ideation19.12.01.003--
Suicide attempt19.12.01.0040.000342%
Systemic lupus erythematosus10.04.03.004; 15.06.02.003; 23.03.02.006---
Therapeutic response decreased08.06.01.016---
Urticaria10.01.06.001; 23.04.02.0010.001164%
Vertigo04.04.01.003; 17.02.12.002--
Visual impairment06.02.10.013---
Vomiting07.01.07.0030.001336%
Lymphatic disorder01.09.01.003---
Musculoskeletal discomfort15.03.04.001---
Connective tissue disorder10.04.04.026; 15.06.01.006---
Malnutrition14.03.02.004---
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene